Dendreon Corporation (NASDAQ:DNDN) dropped 1.46% to $37.90. Canaccord Genuity maintained a 'Buy' on Dendreon with a price target of $60. The company is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.
The stock went up more than 43% year-to-date.
PharmAthene, Inc. (AMEX:PIP) gained 4.74% to $1.75. Earlier this week, the company reported Q2 loss of $0.22, cents better than the analyst estimate of ($0.21). Revenue for the quarter was $4.8 million, which compares to the estimate of $7.00 million.
The stock opened at $1.70 and has a 52-week range of $1.13-$4.24. In the past one month of trading sessions, the stock went up more than 18%.
Cell Therapeutics, Inc. (NASDAQ:CTIC) soared 9.99% to $0.425. Cell Therapeutics, Inc. develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.
Over the past one month of trading sessions, the stock went up more than 15%.
Gilead Sciences, Inc. (NASDAQ:GILD) rose 0.87% to $37. Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics. The Company has operations in North America, Europe and Australia.
Over the past 52-week, the stock had traded within the range of $31.73-$49.50. At current market price, the market capitalization of the company stood at $31.03 billion.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today.
To read our full disclosures please follow the link http://www.wallstreetgrand.com/disclosure.html